Robert S. Landsman

Array ( [id] => 17428444 [patent_doc_number] => 20220056152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-24 [patent_title] => ANTI-HUMAN NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/498091 [patent_app_country] => US [patent_app_date] => 2021-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43783 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17498091 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18808644 [patent_doc_number] => 20230382978 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => ANTIBODY SPECIFIC FOR SARS-COV-2 RECEPTOR BINDING DOMAIN AND THERAPEUTIC METHODS [patent_app_type] => utility [patent_app_number] => 18/031814 [patent_app_country] => US [patent_app_date] => 2021-10-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18031814 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18829703 [patent_doc_number] => 20230398227 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => MEDICINE FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/030203 [patent_app_country] => US [patent_app_date] => 2021-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17117 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18030203 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921494 [patent_doc_number] => 20240024498 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING ANTIBODY-DRUG CONJUGATE, AND USE OF PHARMACEUTICAL COMPOSITION [patent_app_type] => utility [patent_app_number] => 18/029075 [patent_app_country] => US [patent_app_date] => 2021-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18916732 [patent_doc_number] => 11879002 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-23 [patent_title] => Bi-specific therapeutic proteins, in vivo methods of use thereof and encoding nucleic acids thereof [patent_app_type] => utility [patent_app_number] => 17/487120 [patent_app_country] => US [patent_app_date] => 2021-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 17 [patent_no_of_words] => 41014 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17487120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18830869 [patent_doc_number] => 20230399394 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => Antibody Binding to Human IL-33, Preparation Method Therefor, and Use Thereof [patent_app_type] => utility [patent_app_number] => 18/246756 [patent_app_country] => US [patent_app_date] => 2021-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18951 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246756 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902745 [patent_doc_number] => 20240018230 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => METHODS FOR TREATING OR MODULATING AN INFLAMMATORY RESPONSE [patent_app_type] => utility [patent_app_number] => 18/245257 [patent_app_country] => US [patent_app_date] => 2021-09-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15314 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17385626 [patent_doc_number] => 20220033478 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ADENO-ASSOCIATED VIRUS ANTIBODIES AND FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/478645 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22654 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17478645 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754050 [patent_doc_number] => 20230357422 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, FUSION PROTEIN THEREOF, PHARMACEUTICAL COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/245691 [patent_app_country] => US [patent_app_date] => 2021-09-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16653 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245691 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770876 [patent_doc_number] => 20230365678 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => DOSING REGIMENS OF ANTI-ILT4 ANTIBODY OR ITS COMBINATION WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/245590 [patent_app_country] => US [patent_app_date] => 2021-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35098 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754067 [patent_doc_number] => 20230357440 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => BISPECIFIC ANTIBODY AGAINST CD3 AND CD20 IN COMBINATION THERAPY FOR TREATING FOLLICULAR LYMPHOMA [patent_app_type] => utility [patent_app_number] => 18/025205 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30256 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -47 [patent_words_short_claim] => 210 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18025205 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18754044 [patent_doc_number] => 20230357415 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO INTERLEUKIN-4 RECEPTOR ALPHA SUBUNIT AND INTERLEUKIN-5 RECEPTOR ALPHA SUBUNIT, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/024143 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26387 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18817514 [patent_doc_number] => 20230391854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-07 [patent_title] => MONOCLONAL ANTIBODY FOR CORONAVIRUS SPIKE PROTEIN, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/248545 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 454 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248545 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18786131 [patent_doc_number] => 20230374144 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => ANTIBODIES SPECIFICALLY RECOGNIZING INTERLEUKIN-4 RECEPTOR ALPHA AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/044703 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63410 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18044703 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19373923 [patent_doc_number] => 12065472 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-08-20 [patent_title] => Tumor necrosis factor receptor (TNFR) binding protein complex with improved binding and bioactivity [patent_app_type] => utility [patent_app_number] => 17/465186 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 15 [patent_no_of_words] => 18441 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465186 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17314535 [patent_doc_number] => 20210403583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ANTI-CSF1R ANTIBODIES, IL10 FUSION PROTEINS, AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/463427 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29887 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -2 [patent_words_short_claim] => 162 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463427 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582955 [patent_doc_number] => 20230265214 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => COMPOSITIONS AND METHODS FOR DELIVERY OF NUCLEIC ACIDS TO CELLS [patent_app_type] => utility [patent_app_number] => 18/043534 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41094 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -58 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043534 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19441210 [patent_doc_number] => 12091451 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-09-17 [patent_title] => Method of using antibody molecules to detect a proliferation-inducing ligand (APRIL) [patent_app_type] => utility [patent_app_number] => 17/463319 [patent_app_country] => US [patent_app_date] => 2021-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 66 [patent_no_of_words] => 135617 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17463319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709235 [patent_doc_number] => 20230331848 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => PD-1 BINDING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/042650 [patent_app_country] => US [patent_app_date] => 2021-08-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20525 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18042650 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18902743 [patent_doc_number] => 20240018228 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => ANTIBODIES SPECIFIC TO CCL21 AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/043570 [patent_app_country] => US [patent_app_date] => 2021-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 43470 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18043570 [rel_patent_id] =>[rel_patent_doc_number] =>)